CT001 - Nasal spray acute pain
Cessatech pipeline The lead candidate, CT001, a fixed-dose nasal spray for treating acute pain in children. CT002, a non-invasive intranasal sedation for

Cessatech develops its specialty hospital medicines for children and lead program CT001 advances toward near-term commercialization.
cessatech.comCrawled Nov 20, 2026
Cessatech pipeline The lead candidate, CT001, a fixed-dose nasal spray for treating acute pain in children. CT002, a non-invasive intranasal sedation for
CT002 – A non-invasive nasal spray for conscious sedation of children undergoing medical procedures CT002 is a nasal spray intended for procedural
CT003 – A non-invasive, needle-free local anaesthetic gel for paediatric laceration repair CT003 is a ready-to-use, sterile, needle-free local anaesthetic
CT004 – Intravenous melatonin for peadiatric emergence delirium CT004 is being developed for the prevention and management of emergence delirium (ED) in
More than 20 million children annually, alone in Europe, are subject to acute pain at hospitals or ambulances from accidents, incidents or from medical
Only 30% of marketed medicines in the EU are approved for children, and only 50% of the most commonly used are tested in child populations.
A systematic review of 31 studies with off-label prescription rates confirms the continued off-label use of medication in children*). This is especially
Physical restraint of children during painful procedures is used in 79% of Scandinavian emergency departments. 73 % of respondents reported a need for
Giving medicine to children can't be a one-size-fits-all approach. Their changing anatomy and physiology demand tailored trials, formulations, and
Cessatech A/S today announces that Spotlight Stock Market’s listing committee has approved Cessatech’s application for admission to trading the Company’s
Subscribed to DKK 107 million, corresponding to a subscription ratio of approx. 680 percent.
The Board has a wide experience from the entire value chain, which is a strong asset for Cessatech and its future aspirations
Cessatech sponsors Save the Children to support children.
Cessatech A/S today releases its results for the period 6. April – 31 December 2020. The company is on track with Q4 activities and getting ready for an exciting year.
Cessatech has today appointed Anders Dyhr Dombernowsky-Toft to the Board of Directors at the Company’s extraordinary general meeting. The appointment
Studies are still needed to determine the safety and efficacy of drugs that lack FDA labeling for this vulnerable patient population. Drugs were administered off-label in 73.4% of cases to children.
Children differ pharmacokinetically from adults, and medication for adults cannot simply be administered in smaller doses
Corporate Social Responsibility Cessatech A/S is committed to conducting its business responsibly and in alignment with its mission to improve the
Unapproved medicines can cause severe side effects in children and the elderly.
Cessatech targets unmet medical needs in pediatric care, particularly in hospitals and emergency units, through commercial partnerships.
Cessatech develops child-friendly formulations of existing medicines to address unmet pediatric needs in hospitals and emergency settings.
Legal and GDPR Information about Cessatech’s legal notices and GDPR-related data protection practices. Legal notice All rights are reserved by Cessatech
Proveca and Cessatech are advancing regulatory plans for **KemSu (CT001)** after the **European Medicines Agency’s CHMP** reaffirmed its negative opinion on the **Paediatric Use Marketing Authorisation (PUMA)** application. The companies will now determine next steps following the regulatory review process.
Cessatech reports early progress with its sufentanil/ketamine nasal spray, **CT001**, following its US launch. Hospitals engaged with the product provide positive feedback, though commercial success remains unassessed at this stage. The company continues to gather insights from initial market interactions.
Cessatech A/S publishes its second-quarter 2026 financial results and highlights progress in its pediatric hospital medicines pipeline. The late-stage specialty company focuses on developing and commercializing treatments for children. The full report is accessible on the company’s website.
Cessatech’s CT001 (sufentanil/ketamine nasal spray) receives U.S. manufacturing approval from STAQ Pharma, enabling shipment to early-adopter hospitals. The company now begins commercial launch activities for its pediatric pain management product. CT001 targets hospital-based pediatric sedation needs, addressing unmet medical requirements in children.
Proveca plans to seek a re-examination of the European Medicines Agency’s negative opinion on CT001/KemSu, an intranasal sufentanil/ketamine formulation. The Committee for Medicinal Products for Human Use (CHMP) previously rejected the Paediatric Use Marketing Authorisation (PUMA) application for the drug. The company aims to challenge the decision to advance its pediatric pain management candidate.
Cessatech partners with Rigshospitalet to develop **CT004**, an intravenous melatonin formulation targeting **post-anaesthesia delirium** in children. The condition—affecting **25–30% of pediatric patients**—lacks approved treatments. The collaboration aims to advance clinical progress for this underserved area.
Cessatech completes the technology transfer of **CT001**, enabling its availability for acute pediatric pain management in US hospitals. The product advances through a partnership with **STAQ Pharma**, targeting clinical use in children. This milestone follows regulatory and development progress toward broader hospital adoption.